2019
Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals
Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández‐Díaz S, Meyer L, Seng R, Drozd DR, Seage G, Bonnet F, Le Marec F, Moore RD, Reiss P, Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals. Statistics In Medicine 2019, 38: 2428-2446. PMID: 30883859, PMCID: PMC6499640, DOI: 10.1002/sim.8120.Peer-Reviewed Original ResearchConceptsHIV-positive individualsCopies/First-line treatment regimenAIDS Research NetworkAIDS-free survivalCells/Integrated Clinical SystemsHIV-CAUSAL CollaborationOutcomes of interestRisk difference estimatesDirect effectAntiretroviral therapyHIV RNACD4 thresholdTreatment regimenNew regimenTreatment strategiesHIV researchTarget trialsRegimenTherapyResearch NetworkTrialsSurvivalClinical systems
2016
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine 2016, 95: e5133. PMID: 27741139, PMCID: PMC5072966, DOI: 10.1097/md.0000000000005133.Peer-Reviewed Original ResearchConceptsCD4 cell countEfavirenz regimenVirologic failureVirologic outcomesSurvival differencesNucleoside reverse transcriptase inhibitor (NRTI) backboneCell countReverse transcriptase inhibitor backboneAtazanavir-containing regimensAIDS-free survivalHuman immunodeficiency virusImmune deficiency syndromeHIV-CAUSAL CollaborationAtazanavir regimenHazard ratioClinical outcomesImmunodeficiency virusProspective studyDeficiency syndromeMean changeRegimensEfavirenzTime-varying covariatesInhibitor backboneRegimen
2014
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014, 83: 134-141. PMID: 24907236, PMCID: PMC4117168, DOI: 10.1212/wnl.0000000000000564.Peer-Reviewed Original ResearchConceptsHigher CPE scoreLower CPE scoreAntiretroviral therapy regimenProgressive multifocal leukoencephalopathyCPE scoreHIV dementiaHazard ratioCryptococcal meningitisMultifocal leukoencephalopathyTherapy regimenAntiretroviral therapy-naive individualsCNS penetration-effectiveness (CPE) scoreTherapy-naive individualsRespective hazard ratiosCases of toxoplasmosisHIV-CAUSAL CollaborationIncidence of AIDSAntiretroviral penetrationAntiretroviral regimenBaseline regimensInitial regimenNeurologic conditionsNeurologic disordersCNS penetrationRegimen
2010
Virologic and immunologic response to HAART, by age and regimen class
Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, Klein MB, Gebo KA. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010, 24: 2469-2479. PMID: 20829678, PMCID: PMC3136814, DOI: 10.1097/qad.0b013e32833e6d14.Peer-Reviewed Original ResearchConceptsCD4 cell countImmunologic responseNorth American AIDS Cohort CollaborationCell countMean CD4 cell countProtease inhibitor-based regimenNonnucleoside reverse transcriptase inhibitorAntiretroviral-naive adultsInhibitor-based regimenInitial antiretroviral regimenProspective cohort studyConfidence intervalsReverse transcriptase inhibitorImpact of ageInverse probability weightsCohort CollaborationInitial regimenAntiretroviral regimenVirologic responseCohort studyViral loadEligible participantsOdds ratioTranscriptase inhibitorRegimen
2009
HIV infection in the elderly
Gebo KA, Justice A. HIV infection in the elderly. Current Infectious Disease Reports 2009, 11: 246-254. PMID: 19366568, PMCID: PMC3129647, DOI: 10.1007/s11908-009-0036-0.Peer-Reviewed Original ResearchOlder patientsYounger patientsBetter virologic suppressionOlder HIV patientsActive antiretroviral therapyManagement of HIVPrevalence of HIVDrug-drug interactionsAntiretroviral regimenHAART initiationHAART regimenVirologic suppressionAntiretroviral therapyHIV patientsImmunologic benefitsHIV infectionPatientsSide effectsHIVPopulation agesRegimenAgeHAARTComorbiditiesTherapy